
Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases. BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress. BioNTech was founded in 2008 by scientists and physicians to translate science into survival by combining fundamental research and operational excellence. At BioNTech, we have been conducting fundamental research of mRNA technologies in the field of individualized cancer medicine for more than a decade. Some of our colleagues, including our co-founders, have been researching and developing mRNA-based vaccines for more than 25 years. Ready to join us on this journey? Explore the opportunities and become part of a team that aspires to turn bold ideas into real-world solutions: https://www.biontech.com/int/en/home/careers.html 🔗 Privacy Statement: https://www.biontech.com/int/en/home/data-privacy-statement.html 🔗 Imprint: https://www.biontech.com/int/en/home/imprint.html
We're tracking BioNTech SE's market expansion
New Partnerships activity — 2 fresh signals just appeared.
How BioNTech SE's international expansion compares to its competitors
Bars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
BioNTech SEYou | 0 | 0 | — | 0 | 0 |
Director Safety Physician
View postingMainz, Rhineland-Palatinate, Germany · 3d ago
Associate Technician Facility Management (m/w/d)
View postingFrankfurt Rhine-Main Metropolitan Area · 4d ago
Director, Regional Logistics Operations US
View postingGaithersburg, MD · 2w ago
No active campaigns
Sign up to track this company and get alerted the moment something changes.
BioNTech's experimental breast cancer drug outperformed Roche's Kadcyla in a Chinese trial, showing promise for future growth beyond Covid vaccines.
Pfizer-BioNTech's 2025-2026 mRNA COVID-19 vaccine shows strong immune response in elderly and high-risk groups, with 4x increase in neutralizing antibodies against LP.8.1 variant.
BioNTech reports clinical breakthroughs in COVID vaccine and cancer drug BNT327, potentially boosting sales and accelerating oncology focus.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about BioNTech SE's business, markets, and growth signals.

© 2026 Pubrio. All rights reserved.